Latest Articles

Publication Date
All News Scientific
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Investor Relations | Karyopharm Therapeutics

Published: Dec. 3, 2024, 12:01 p.m.
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Kilgore News Herald

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Kilgore News Herald

Published: Dec. 3, 2024, noon
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - PR Newswire

Karyopharm Therapeutics Provides Endometrial Cancer Program Update PR Newswire

Published: Dec. 3, 2024, noon
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Longview News-Journal

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Longview News-Journal

Published: Dec. 3, 2024, noon
Read Full Article
Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News - StockTitan

Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News StockTitan

Published: Dec. 3, 2024, noon
Read Full Article
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast

Hutchmed endometrial cancer treatment gets conditional approval in China ShareCast

Published: Dec. 3, 2024, 10:28 a.m.
Read Full Article
NMPA greenlights new endometrial cancer therapy By Investing.com - Investing.com Australia

NMPA greenlights new endometrial cancer therapy By Investing.com Investing.com Australia

Published: Dec. 3, 2024, 10:15 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!